Trial Failure Still Yields Insights for Uterine Leiomyosarcoma
Experts weigh in on valuable findings that can be gleaned despite the fact that the phase III trial did not generate clinically meaningful results.
Percentage of Cancer Due to Excess Body Weight Varies by State
The highest rates of excess body weight–associated cancer were found in the South and Midwest, Alaska, and the District of Columbia, according to the study.
Discussing Advances in Chemo Brain Treatment
Cancer Network spoke with Tracy D. Vannorsdall, PhD and Patricia Ganz, MD about treatment methods for cancer-related cognitive impairment.
Interrogating Ras-ERK Interactions and Roles in Tumor Cell Biology
Cancer Network spoke with Dr. Chuan-Hsiang Huang about his lab’s research on Ras-ERK protein interactions within cancer cells.
Identifying Cancer-Driving Gene Mutations
Cancer Network spoke with Dr. Rachel Karchin about the contemporary search for cancer-driving gene mutations.
Link Between Placebos and Severe Adverse Events in Clinical Trials
A study shows patients in the placebo group of clinical trials testing against targeted and immunotherapy cancer drugs may experience a high rate of grade 3/4 adverse events.
Three Key Messages to Guide the Success of Oncology Biosimilars
The authors of a European review provide recommendations for all stakeholders on smooth implementation of cancer biosimilar agents.
The Role of Biosimilars in Value-Based Oncology Care
Can expanded use of oncology biosimilar agents and supportive care agents help support the CMS' value-based care efforts?
Understanding The Regulatory Roles of lncRNA
Cancer Network speaks with Dr. Pavel Sumazin about his ongoing efforts to further understand how lncRNA influence genes with known function in cancers.
Alternative RNA Splicing and Tumor Progression
Cancer Network speaks with Eduardo Eyras, PhD about the emerging roles of RNA splicing variants in cancer treatment.
Comparing Field Treatment for Actinic Keratosis
Researchers evaluated the efficacy of 5-florouracil vs imiquimod in preventing site-specific keratinocyte carcinoma.
Cancer Network Conferences
Does a Cancer Diagnosis Increase Suicide Risk?
Researchers in England investigated whether risk for suicide was elevated in cancer patients, and which cancer types might have the greatest risk.
Do Oral Side Effects Affect Fentanyl Delivery in Head & Neck Cancer Patients?
Erin McMenamin, CRNP, of Penn Medicine, discusses how oral side effects affect head and neck cancer patients.
Managing Afib in Cancer Patients Taking BTK Inhibitors
Cancer Network speaks with Dr. Leon Ptaszek about managing cancer patients who have atrial fibrillation and are being treated with BTK inhibitors.
Are Patients Willing to Travel for Cancer Surgery?
Survey results published in JAMA Network Open looked at motivating factors behind patient travel and how far they were willing to go for treatment.
Is the FDA’s Biosimilar Action Plan Adequate?
Gary H. Lyman, MD, MPH, says the plan does not address several significant concerns, such as delay tactics that limit prompt access to biosimilars.
Do Targeted Agents Aid Melanoma Immunotherapy?
Guy Ben-Betzalel, MD spoke with Cancer Network about the emerging role of targeted BRAF+MEK inhibition in antitumor immunity.
Emerging Targets in Cancer Immunotherapy
Professor Lana E. Kandalaft, PharmD, PhD spoke with Cancer Network about the next generation of cancer immunotherapy.
Early Insights into Biosimilar Cost Savings in the United States
A recent study in JAMA Oncology examined the average daily cost of biosimilar filgrastim-sndz compared with the brand name biologic.
Managing CAR T-Cell Therapy in Patients With Hematologic Malignancies
Stephanie Jackson, MSN, RN speaks with Cancer Network about the role oncology nurses play in managing patients with hematologic malignancies who are undergoing CAR T-cell therapy.
Pros and Cons of Dietary Strategies Popular Among Cancer Patients
This article discusses some of the popular diets that cancer patients pursue, and the positive and negative aspects associated with these diets.
The Verdict on IMRT Plus Doxorubicin in Unresectable Thyroid Cancer
A study in Thyroid evaluated the safety and efficacy of concurrent intensity-modulated radiation therapy and doxorubicin in thyroid cancer.
Could Switching Opioids in Cancer Patients Provide Relief?
We spoke with Erin McMenamin, CRNP, of Penn Medicine, about the recent study on opioid switching in cancer patients.
New Study Looks at Selumetinib for Treating Differentiated Thyroid Cancer
Interim results are in from a study evaluating whether adding selumetinib to RAI improves complete response, irrespective of MAPK pathway alterations.
Does Eating Organic Foods Decrease Cancer Risk?
We spoke with Kelly Hogan, MS, RD, about the recent JAMA study on the association between organic food consumption and cancer risk.
Is ADT Linked to Dementia in Men with Prostate Cancer Receiving Definitive Radiotherapy?
The findings of this study, recently published in JAMA Oncology, directly contradict previously conducted research on the same topic.
New Expert Guidance on EBRT in Men with Early-Stage Prostate Cancer
Oncologists now have some clarification on the use of moderate hypofractionation and ultrahypofractionation from ASTRO, ASCO, and the AUA.
TNFR2's Role in Influencing Tumor Tissue
Dr. Denise Faustman spoke with Cancer Network about TNFR2 and its emerging role in understanding regulatory T-cell behavior.
Epigenetics, BRCA, and Inherited Cancers: Dr. Newman Connects the Dots
Dr. William Newman spoke with Cancer Network about the roles of epigenetic silencing in heritable cancer syndromes.
